三阴性乳腺癌中预测铂类药物疗效的遗传标记物筛查及其机制
序号 | 标题 | 类型 | 作者 |
---|---|---|---|
1 | Stem cell marker aldehyde dehydrogenase 1 (ALDH1)-expressing cells are enriched in triple-negative breast cancer. | 期刊论文 | Li, Huihui|Ma, Fei|Wang, Haijuan|Lin, Chen|Fan, Ying|Zhang, Xueyan|Qian, Haili|Xu, Binghe| |
2 | There is no association between microRNA gene polymorphisms and risk of triple negative breast cancer in a Chinese Han population. | 期刊论文 | Ma, Fei|Zhang, Ping|Lin, Dongxin|Yu, Dianke|Yuan, Peng|Wang, Jiayu|Fan, Yin|Xu, Binghe| |
3 | EGFR基因rs2293347多态对吉非替尼治疗非小细胞肺癌临床疗效的影响 | 期刊论文 | 马飞|徐兵河|林东昕|孙瞳|石远凯| |
4 | TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy | 期刊论文 | Jiayu Wang|Binghe Xu|Peng Yuan|Pin Zhang|Qing Li|Fei Ma|Ying Fan| |
5 | 评价肿瘤风险与治疗反应的遗传标记物研究及其应用 | 奖励 | 孙燕|林东昕|马飞|袁芃|吴晨|于典科|张雪梅|孙瞳|杨明| |
6 | ERCC2 rs1799793多态性与三阴性乳腺癌铂类化疗疗效的关系 | 期刊论文 | 徐兵河|马飞|王佳玉|袁芃|蔡锐刚|樊英|李俏|张频|李青| |